Sort
64,565 grants matching “drug discovery”
Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer
$1,000,000Alexander Federation · Talus Bioscience, Inc. · R44 · FY2024 · CA
Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool
$1,000,000Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2022 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori
$1,000,000Kenneth Coleman · Arietis · R44 · FY2013 · AI
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
$1,000,000David H Haussler · University Of California Santa Cruz · U24 · FY2009 · CA
Selective Decorporation Agents for NIAID
$1,000,000Benjamin P Warner · Icagen, Inc. · R44 · FY2013 · AI
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease
$1,000,000James Lee · Id4pharma, Llc · R44 · FY2019 · CA
Acquisition of High Performance Data and Computing Infrastructure to Advance Biomedical Research
$1,000,000Thomas Furlani · State University Of New York At Buffalo · S10 · FY2019 · OD
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2020 · CA
Fully-Automated Lesion Characterization in Ultrawide-Field Retinal Images
$1,000,000Sandeep Bhat · Eyenuk, Inc. · R44 · FY2020 · EY
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib
$1,000,000Richard W Scott · Polymedix, Inc, · R44 · FY2012 · AI
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$1,000,000Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2020 · CA
Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe
$1,000,000Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2011 · AI
NQVL:QSTD:Pilot: Distributed-Entanglement Quantum Sensing of Chemical Properties (DQS-CP)
$1,000,000Ezekiel Johnston-Halperin · Ohio State University, The · · FY2024 · MPS
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis
$1,000,000Michelle M. Butler · Microbiotix, Inc · R44 · FY2020 · AI
Collaborative Research: EPiQC: Enabling Practical-Scale Quantum Computation
$1,000,000Andrew A Houck · Princeton University · · FY2018 · CSE
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
$1,000,000Christopher John Burns · Venatorx Pharmaceuticals, Inc. · R44 · FY2019 · AI
Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer
$1,000,000Alexander Federation · Talus Bioscience, Inc. · R44 · FY2023 · CA
Assigning mode of action to phenotypically discovered anticancer leads.
$1,000,000Sergei S Makarov · Attagene, Inc. · R44 · FY2024 · CA
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry
$1,000,000Brett D Welch · Navigen, Inc. · R44 · FY2016 · AI
Scaling function-first antibody discovery leveraging memory B cells
$1,000,000Joseph De Rutte · Partillion Bioscience Corporation · R44 · FY2025 · AI
Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies
$1,000,000Kristin M Bircsak · Mimetas Us, Inc. · R44 · FY2022 · DK
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
Derivation of human pluripotent stem cells using small molecules
$1,000,000Yanhong Shi · Beckman Research Institute/City Of Hope · RC1 · FY2010 · NS
The Southwest National Primate Research Center
$1,000,000Kenneth Parkhurst Trevett · Texas Biomedical Research Institute · P51 · FY2010 · RR
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci
$1,000,000Terry Roemer · Prokaryotics, Inc. · R44 · FY2020 · AI